MediPrint Ophthalmics Advances LL-BMT1, a Sustained Drug Delivery Contact Lens for Glaucoma

MediPrint Ophthalmics has announced significant progress in its glaucoma drug delivery program following the successful completion of its Phase 2b clinical trial for LL-BMT1. The company is preparing for a 2025 meeting with the US Food and Drug Administration (FDA) to discuss Phase 3 clinical studies.

LL-BMT1: A Breakthrough in Glaucoma Treatment

LL-BMT1 utilizes a 3D-printed, drug-eluting contact lens designed to provide sustained drug delivery for glaucoma management. This innovative approach aims to reduce treatment burden and improve patient compliance by eliminating the need for frequent eye drops.

The Phase 2b trial demonstrated that:

       • LL-BMT1 delivered therapeutic results comparable to 0.01% bimatoprost eye drops.

       • Once-a-week dosing with LL-BMT1 provided a significant advantage over daily or multiple-times-per-day eye drop regimens.

This advancement has the potential to redefine adherence in glaucoma care, offering a convenient, effective alternative to traditional treatments.

New Patent Secures Long-Term Protection

On December 31, 2024, MediPrint was granted US Patent No. 12,178,904 by the US Patent and Trademark Office (USPTO). This patent covers MediPrint’s proprietary chemistry related to the sustained release of prostaglandins via contact lenses and extends the company’s patent protection through 2043. With this latest addition, MediPrint’s global patent portfolio now includes 29 granted patents, with several additional patents pending.

Industry Presentation at Glaucoma 360 New Horizons Forum

MediPrint showcased its advancements in sustained drug delivery at the Glaucoma 360 New Horizons Forum on February 7, 2025, in San Francisco, California.

During the presentation, the company highlighted:

       • The clinical success of LL-BMT1 in reducing intraocular pressure (IOP).

       • The potential for LL-BMT1 to improve patient adherence by simplifying glaucoma treatment regimens.

       • The broader implications of drug-eluting contact lens technology in the management of chronic ocular diseases.

Pioneering the Future of Glaucoma Care

With its FDA meeting on the horizon and a strong patent portfolio in place, MediPrint Ophthalmics is poised to advance LL-BMT1 into Phase 3 trials. The company remains committed to developing innovative solutions that simplify eye care delivery, improve treatment outcomes, and enhance patients' quality of life.

The success of LL-BMT1 represents a promising step forward in the evolution of glaucoma treatment, demonstrating how sustained drug delivery through contact lenses can provide consistent therapeutic benefits while reducing the burden of daily eye drop administration.